Spiros D. Garbis

Thuris Corp. develops medical devices. It develops pharmaceuticals for CNS Orphan and niche indications including, a stroke-related condition, peripheral neuropathy and Huntington's disease. It develops pharmaceuticals for cluster headaches, depression and mild cognitive impairment, a precursor of Alzheimer's disease. The company is also developing a non-invasive medical device that will assist in the diagnosis of psychiatric and neurological disorders over a broad range of brain-related conditions. Thuris is headquartered in Irvine, CA.

Ancile Pharmaceuticals, Inc. develops and manufactures pharmaceuticals. The private company is based in San Diego, CA.

Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then.

Dyania Health, Inc. develops a clinical research platform for pharmacies and hospitals. The company is based in Los Angeles, CA. The company was founded by Eirini Schlosser and Dimitrios Iliopoulos. Eirini Schlosser has been the CEO since incorporation.